SCHEDULE 13G/A: Janus Henderson Group PLC Discloses 2.2% Stake in IMMUNOME INC via Amended Schedule 13G Filing

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership stake in IMMUNOME INC, held for investment purposes in the ordinary course of business.

Summary

• Janus Henderson Group PLC, a Jersey-based parent holding company and investment adviser, has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in IMMUNOME INC.
• The filing indicates that Janus Henderson Group PLC beneficially owns an aggregate of 1,914,758 shares of IMMUNOME INC's Common Stock.
• This ownership represents 2.2% of the total class of securities.
• The shares are held with shared voting power and shared dispositive power of 1,914,758 shares.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of IMMUNOME INC.
• Indirect subsidiaries of Janus Henderson, including JHIUS, JHIUKL, and JHIAIFML, are registered investment advisers furnishing investment advice to Managed Portfolios, with JHIUS specifically deemed to be the beneficial owner of 1,886,796 shares.

Sentiment

Score: 5

Explanation: Neutral. The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the perception of the company's financial health or prospects. It indicates a passive investment.

Positives

• Indicates continued institutional investment interest in IMMUNOME INC by a major asset manager, Janus Henderson Group PLC.
• The filing explicitly states the shares are held in the ordinary course of business and not for control purposes, suggesting a passive investment stance.

Future Outlook

NA

Management Comments

• Kristin Mariani, Head of North America Compliance for Janus Henderson Group PLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of IMMUNOME INC.

Industry Context

This filing reflects a routine disclosure of a passive investment stake by a large asset manager in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape beyond indicating continued institutional interest in the sector.

Stakeholder Impact

• Informs shareholders and the market about the passive investment stake held by Janus Henderson Group PLC.
• Provides transparency regarding institutional ownership in IMMUNOME INC.

Key Dates

Keywords

IMMUNOME INC, Janus Henderson Group PLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Investment Adviser, SEC Filing, Equity Stake